EP2863747A4 - Novel cabergoline derivatives - Google Patents

Novel cabergoline derivatives

Info

Publication number: EP2863747A4
Authority: EP; European Patent Office
Prior art keywords: derivatives; novel; novel cabergoline; cabergoline derivatives; cabergoline
Prior art date: 2012-06-22
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Withdrawn

Application number

EP12879191.0A

Other languages

German (de)

French (fr)

Other versions

EP2863747A1 (en

Inventor

Jian Zhang

Thomas A Armer

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

MAP Pharmaceuticals Inc

Original Assignee

MAP Pharmaceuticals Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-06-22

Filing date

2012-06-22

Publication date

2015-12-23

2012-06-22 Application filed by MAP Pharmaceuticals Inc filed Critical MAP Pharmaceuticals Inc

2015-04-29 Publication of EP2863747A1 publication Critical patent/EP2863747A1/en

2015-12-23 Publication of EP2863747A4 publication Critical patent/EP2863747A4/en

Status Withdrawn legal-status Critical Current

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D457/00—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid
- C07D457/04—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 8
- C07D457/06—Lysergic acid amides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D457/00—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid
- C07D457/04—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 8

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Psychology (AREA)
Pain & Pain Management (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

EP12879191.0A 2012-06-22 2012-06-22 Novel cabergoline derivatives Withdrawn EP2863747A4 (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
PCT/US2012/043687 WO2013191704A1 (en)	2012-06-22	2012-06-22	Novel cabergoline derivatives

Publications (2)

Publication Number	Publication Date
EP2863747A1 EP2863747A1 (en)	2015-04-29
EP2863747A4 true EP2863747A4 (en)	2015-12-23

Family

ID=49769156

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EP12879191.0A Withdrawn EP2863747A4 (en)	2012-06-22	2012-06-22	Novel cabergoline derivatives

Country Status (11)

Country	Link
EP (1)	EP2863747A4 (en)
JP (1)	JP2015525239A (en)
CN (1)	CN104822264A (en)
AU (1)	AU2012382929A1 (en)
BR (1)	BR112014031945A2 (en)
CA (1)	CA2876321A1 (en)
HK (1)	HK1208997A1 (en)
IL (1)	IL236310A0 (en)
RU (1)	RU2014153672A (en)
SG (1)	SG11201408567PA (en)
WO (1)	WO2013191704A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
BR112017015487A2 (en) *	2015-01-20	2018-01-30	Xoc Pharmaceuticals Inc	COMPOUND; COMPOSITION; METHOD OF TREATMENT AND / OR PREVENTION OF MIGRAINE, ALS, ALZHEIMER'S DISEASE, PARKINSON'S DISEASE, EXTRAPYRIMIDAL DISORDERS, DEPRESSION, NAUSEA, AEMESIS, SYNDROME OF THE WASTE LEGS, INSOMENESS, HYGERNESS, AGING , ANXIETY, DRUG DEPENDENCIES, DYSTONIA, PARASSONIA OR HYPERLACTINEMIA IN AN INDIVIDUAL; AGONIZATION METHODS OF D2, 5-HT1D, 5-HT1A AND 5-HT2C RECEPTORS, IN AN INDIVIDUAL; ANTAGONIZATION METHOD OF THE D3 RECEPTOR IN AN INDIVIDUAL; METHODS OF SELECTIVE AGONIZATION OF RECEPTORS 5 -HT1D, AND 5-HT2C, METHOD OF PROVIDING FUNCTIONAL ANTAGONIST ACTIVITY IN RECEPTOR 5 -HT2B OR IN RECEIVER 5-HT7, OR IN BOTH, IN AN INDIVIDUAL; METHOD OF PROVIDING FUNCTIONAL ANTAGONIST ACTIVITY IN ADRENERGIC RECEPTORS IN AN INDIVIDUAL
CN106866656A (en) *	2017-02-28	2017-06-20	西南交通大学	One class ergoline derivatives and its purposes in prevention and treatment mental illness
EP3530651A1 (en) *	2018-02-21	2019-08-28	Adamed sp. z o.o.	Indole and benzimidazole derivatives as dual 5-ht2a and 5-ht6 receptor antagonists
WO2022153266A1 (en)	2021-01-15	2022-07-21	Beckley Psytech Limited	Ergoline analogues
US12264131B2 (en)	2022-08-19	2025-04-01	Beckley Psytech Limited	Pharmaceutically acceptable salts and compositions thereof
US12246005B2 (en)	2023-06-13	2025-03-11	Beckley Psytech Limited	5-methoxy-n,n-dimethyltryptamine (5-MeO-DMT) formulations

Citations (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4526892A (en) *	1981-03-03	1985-07-02	Farmitalia Carlo Erba, S.P.A.	Dimethylaminoalkyl-3-(ergoline-8'βcarbonyl)-ureas
WO1990012796A1 (en) *	1989-04-21	1990-11-01	Schering Aktiengesellschaft Berlin Und Bergkamen	8-beta-substituted ergolines, a process for manufacturing them, and their use
US5705510A (en) *	1993-08-18	1998-01-06	Alcon Laboratories, Inc.	Use of cabergoline and related ergoline derivatives for controlling intraocular pressure
CZ287176B6 (en) *	1997-10-03	2000-10-11	Galena A. S.	Process for preparing ergoline derivatives
WO2004069252A1 (en) *	2003-02-05	2004-08-19	Pharmacia Italia Spa	Cabergoline for the prophylactic treatment of migraine
WO2005085243A2 (en) *	2004-03-04	2005-09-15	Richter Gedeon Vegyészeti Gyár Rt.	Process for the preparation of cabergoline
US7217822B2 (en) *	2005-03-17	2007-05-15	Synthon Ip Inc.	Process for making cabergoline
EP2067780A1 (en) *	2007-12-07	2009-06-10	Axxonis Pharma AG	Ergoline derivatives as selective radical scavengers for neurons
WO2010081036A2 (en) *	2009-01-09	2010-07-15	President And Fellows Of Harvard College	Fluorine containing compounds and methods of use thereof
WO2013095708A1 (en) *	2011-12-21	2013-06-27	Map Pharmaceuticals, Inc.	Novel neuromodulatory compounds

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DK338789A (en) *	1988-07-15	1990-01-16	Schering Ag	2-SUBSTITUTED ERGOLINYLURINE DERIVATIVES AND PROCEDURES FOR THE PRODUCTION THEREOF, THEIR USE AS MEDICINES AND INTERMEDIATES FOR THE PRODUCTION THEREOF
GB0307377D0 (en) *	2003-03-31	2003-05-07	Merad Pharmaceuticals Ltd	Ergoline derivatives
GB0511060D0 (en) *	2005-05-31	2005-07-06	Novartis Ag	Organic compounds
EP2419425A4 (en) *	2009-04-15	2012-08-29	Astrazeneca Ab	Imidazole substituted pyrimidines useful in the treatment of glycogen synthase kinase 3 related disorders such as alzheimer's disease

2012
- 2012-06-22 CN CN201280075321.7A patent/CN104822264A/en active Pending
- 2012-06-22 BR BR112014031945A patent/BR112014031945A2/en not_active IP Right Cessation
- 2012-06-22 RU RU2014153672A patent/RU2014153672A/en unknown
- 2012-06-22 JP JP2015518385A patent/JP2015525239A/en active Pending
- 2012-06-22 SG SG11201408567PA patent/SG11201408567PA/en unknown
- 2012-06-22 HK HK15109927.2A patent/HK1208997A1/en unknown
- 2012-06-22 AU AU2012382929A patent/AU2012382929A1/en not_active Abandoned
- 2012-06-22 CA CA2876321A patent/CA2876321A1/en not_active Abandoned
- 2012-06-22 EP EP12879191.0A patent/EP2863747A4/en not_active Withdrawn
- 2012-06-22 WO PCT/US2012/043687 patent/WO2013191704A1/en not_active Ceased
2014
- 2014-12-17 IL IL236310A patent/IL236310A0/en unknown

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4526892A (en) *	1981-03-03	1985-07-02	Farmitalia Carlo Erba, S.P.A.	Dimethylaminoalkyl-3-(ergoline-8'βcarbonyl)-ureas
WO1990012796A1 (en) *	1989-04-21	1990-11-01	Schering Aktiengesellschaft Berlin Und Bergkamen	8-beta-substituted ergolines, a process for manufacturing them, and their use
US5705510A (en) *	1993-08-18	1998-01-06	Alcon Laboratories, Inc.	Use of cabergoline and related ergoline derivatives for controlling intraocular pressure
CZ287176B6 (en) *	1997-10-03	2000-10-11	Galena A. S.	Process for preparing ergoline derivatives
WO2004069252A1 (en) *	2003-02-05	2004-08-19	Pharmacia Italia Spa	Cabergoline for the prophylactic treatment of migraine
WO2005085243A2 (en) *	2004-03-04	2005-09-15	Richter Gedeon Vegyészeti Gyár Rt.	Process for the preparation of cabergoline
US7217822B2 (en) *	2005-03-17	2007-05-15	Synthon Ip Inc.	Process for making cabergoline
EP2067780A1 (en) *	2007-12-07	2009-06-10	Axxonis Pharma AG	Ergoline derivatives as selective radical scavengers for neurons
WO2010081036A2 (en) *	2009-01-09	2010-07-15	President And Fellows Of Harvard College	Fluorine containing compounds and methods of use thereof
WO2013095708A1 (en) *	2011-12-21	2013-06-27	Map Pharmaceuticals, Inc.	Novel neuromodulatory compounds

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
A. KEKEWSKA ET AL: "The Bulky N(6) Substituent of Cabergoline Is Responsible for Agonism of This Drug at 5-Hydroxytryptamine (5-HT)2A and 5-HT2B Receptors and Thus Is a Determinant of Valvular Heart Disease", JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, vol. 338, no. 1, 1 July 2011 (2011-07-01), US, pages 381 - 391, XP055228644, ISSN: 0022-3565, DOI: 10.1124/jpet.111.181255 *
BRAMBILLA E ET AL: "Synthesis and nidation inhibitory activity of a new class of ergoline derivatives", EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, EDITIONS SCIENTIFIQUE ELSEVIER, PARIS, FR, vol. 24, no. 4, 1 July 1989 (1989-07-01), pages 421 - 426, XP023870591, ISSN: 0223-5234, [retrieved on 19890701], DOI: 10.1016/0223-5234(89)90087-1 *
MANTEGANI S ET AL: "Serotonergic ergoline derivatives", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, PERGAMON, AMSTERDAM, NL, vol. 8, no. 9, 1 May 1998 (1998-05-01), pages 1117 - 1122, XP004137031, ISSN: 0960-894X, DOI: 10.1016/S0960-894X(98)00166-8 *
MIYAGI M ET AL: "DOPAMINE RECEPTOR AFFINITIES IN VITRO AND STEREOTYPIC ACTIVITIES IN VIVO OF CABERGOLINE IN RATS", BIOLOGICAL & PHARMACEUTICAL BULLETIN (OF JAPAN), PHARMACEUTICAL SOCIETY OF JAPAN, TOKYO, JP, vol. 19, no. 9, 1 January 1996 (1996-01-01), pages 1210 - 1213, XP009040256, ISSN: 0918-6158 *
See also references of WO2013191704A1 *

Also Published As

Publication number	Publication date
IL236310A0 (en)	2015-02-26
WO2013191704A1 (en)	2013-12-27
EP2863747A1 (en)	2015-04-29
AU2012382929A1 (en)	2015-02-05
BR112014031945A2 (en)	2017-06-27
SG11201408567PA (en)	2015-02-27
CA2876321A1 (en)	2013-12-27
RU2014153672A (en)	2016-08-10
CN104822264A (en)	2015-08-05
HK1208997A1 (en)	2016-03-24
JP2015525239A (en)	2015-09-03

Publication	Publication Date	Title
ZA201409422B (en)	2021-05-26	Benzimidazole-proline derivatives
ZA201500345B (en)	2015-12-23	New bicyclic derivatives
ZA201408876B (en)	2017-06-28	Pyrrolotriazinone derivatives
AP2015008502A0 (en)	2015-06-30	Novel quinolone derivatives
PL2838883T3 (en)	2018-05-30	New phenyl-tetrahydroisoquinoline derivatives
ZA201502175B (en)	2018-05-30	Oxazolidin-2-one-pyrimidine derivatives
IL236295A (en)	2016-09-29	Indanesulfamide derivative
IL239492A0 (en)	2015-08-31	Novel methysergide derivatives
IL236310A0 (en)	2015-02-26	Novel cabergoline derivatives
ZA201405108B (en)	2015-10-28	Substituted phenylazole derivative
PT2873660T (en)	2016-12-05	Indolecarboxamide derivative
SG11201404325VA (en)	2014-08-28	Pyrimidooxazocine derivatives as mtor - inhibitors

Legal Events

Date	Code	Title	Description
2015-03-27	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
2015-04-29	17P	Request for examination filed	Effective date: 20150112
2015-04-29	AK	Designated contracting states	Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
2015-04-29	AX	Request for extension of the european patent	Extension state: BA ME
2015-09-30	DAX	Request for extension of the european patent (deleted)
2015-11-18	RIN1	Information on inventor provided before grant (corrected)	Inventor name: ZHANG, JIAN Inventor name: ARMER, THOMAS, A.
2015-12-23	RA4	Supplementary search report drawn up and despatched (corrected)	Effective date: 20151125
2015-12-23	RIC1	Information provided on ipc code assigned before grant	Ipc: A61P 25/06 20060101ALI20151119BHEP Ipc: A61K 31/44 20060101AFI20151119BHEP Ipc: C07D 457/06 20060101ALI20151119BHEP Ipc: A61P 25/16 20060101ALI20151119BHEP Ipc: C07D 457/04 20060101ALI20151119BHEP
2016-03-24	REG	Reference to a national code	Ref country code: HK Ref legal event code: DE Ref document number: 1208997 Country of ref document: HK
2016-11-25	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN
2016-12-28	18D	Application deemed to be withdrawn	Effective date: 20160622
2022-01-14	REG	Reference to a national code	Ref country code: HK Ref legal event code: WD Ref document number: 1208997 Country of ref document: HK